Burning Rock to Participate in Morgan Stanley 2020 Healthcare Conference
Burning Rock Biotech Limited (NASDAQ: BNR) will participate in the Morgan Stanley Virtual Healthcare Conference on September 17 at 8:00 a.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Burning Rock Biotech Limited (NASDAQ: BNR) will participate in the Morgan Stanley Virtual Healthcare Conference on September 17 at 8:00 a.m. Eastern Time. The company's management will engage in a fireside chat, allowing for inquiries through Morgan Stanley sales representatives. Burning Rock specializes in precision oncology using next-generation sequencing (NGS) technology, holding a leading market share in China for NGS-based therapy selection testing with over 185,000 tests conducted. The firm is also advancing NGS-based cancer early detection into clinical validation.
Details
News Market Reaction – BNR
The recorded move for BNR in the trading session of this news was -4.33%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SHANGHAI, China, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR) today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference.
Burning Rock’s management is scheduled for a fireside chat on Thursday, September 17 at 8:00 a.m. Eastern Time (8:00 pm Hong Kong time). Interested parties may request more information by contacting their Morgan Stanley sales representatives.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 185,000 tissue and liquid-based tests completed cumulatively, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
For more information about Burning Rock, please visit: www.brbiotech.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.